Investigational drug · Phase 3
JSKN016
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
8
Any phase or sponsor naming "JSKN016"
First trial start
2025
Jan 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JSKN016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer
- Inoperable Locally Advanced HER2-Negative Breast Cancer
- Metastatic HER2-Negative Breast Cancer
- Advanced Non-small Cell Lung Cancer
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer (LABC)
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JSKN016" as an intervention, largest first.
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CarePivotal-lookingRecruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07533123 · 364 participants (planned) · Start Mar 17, 2026 · Primary completion Mar 17, 2029
Drug: JSKN016 Injection; Eribulin Mcsilate Injection and 4 more · For: Triple Negative Breast Cancer
Sites: Guangzhou, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06868732 · 288 participants (planned) · Start Apr 2, 2025 · Primary completion Jun 30, 2028
Drug: JSKN016; Carboplatin and 5 more · For: Advanced Non-small Cell Lung Cancer
Sites: Guangzhou, China
- Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical StudyPivotal-lookingNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06775483 · 220 participants (planned) · Start Jan 17, 2025 · Primary completion Jun 30, 2027
Drug: JSKN016; Docetaxel · For: Advanced Non-small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06942234 · 180 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 30, 2027
Drug: JSKN016; Capecitabine and 3 more · For: Inoperable Locally Advanced HER2-Negative Breast Cancer; Metastatic HER2-Negative Breast Cancer
Sites: Shanghai, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06592417 · 140 participants (planned) · Start Apr 30, 2024 · Primary completion May 17, 2026
Drug: JSKN016 injection · For: Advanced Malignant Solid Tumor
Sites: Fuzhou, China; Guangzhou, China
- JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast CancerNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07336771 · 60 participants (planned) · Start Jan 2026 · Primary completion Dec 2027
Drug: JSKN016 Q2W; JSKN016 Q3W and 1 more · For: Metastatic Breast Cancer; Locally Advanced Breast Cancer (LABC)
Sites: Shanghai, China
- Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer PatientsNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT07493980 · 54 participants (planned) · Start Mar 2026 · Primary completion Jan 2027
Drug: JSKN016 + Toripalimab + Carboplatin · For: NSCLC Stage II
Sites: Shanghai, China
- JSKN016HC in Patients With Advanced or Metastatic Solid Malignant TumorsNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07475559 · 42 participants (planned) · Start Mar 1, 2026 · Primary completion Jul 1, 2028
Drug: JSKN016HC · For: Advanced Solid Tumor Malignancies
Sites: Sydney, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.
Ji X, Yang Y, Ma C, et al. · Cancer Chemother Pharmacol 2026
Also in development for Triple Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- FDA018-ADCPhase 31 trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.